Access to medicine is a fundamental human right. Cancer, diabetes, anaemia, rheumatoid arthritis, multiple sclerosis and other life-threatening and rare illnesses are often treated with what is known as biological drugs. Insulin, growth hormone, erythropoietin, monoclonal antibodies are biotechnological products produced from living cells. Original biologic medicines are often expensive. However, it is now possible to produce biosimilar drugs, at a much lower cost, which would reduce the price and give more patients access to medicine.

To ensure patients on the African continent have access to treatment, there is a tremendous need to develop our ability to produce biologics. Come join us to hear how we can foster domestic capacity for the production of biosimilars on the African continent. Promoting and creating a culture for biosimilars together!

**SPEAKERS**

**Lawrence Banks**
ICGEB Director-General
International Centre for Genetic Engineering and Biotechnology, Trieste, Italy

**Mmboneni Muofhe**
Deputy Director-General (Technology Innovation), South African Department of Science and Innovation

**Nhlanhla Msomi**
South African Biotechnology Specialist, South African Governor to the ICGEB Board of Governors

**Natasa Skoko**
Group Leader, Biotechnology Development, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy

---

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 709517